title: [Effect of complex vaccination against pneumococcal, Haemophilus type b infections and influenza in patients with chronic obstructive pulmonary disease].
abstract: OBJECTIVE
  Determination of the effect of complex vaccination with Pneumo-23, Hiberix, Grippol plus on sputum bacterial content 6 months after the vaccination of patients with chronic obstructive pulmonary disease (COPD) compared with unvaccinated patients.
  
  
  METHODS
  Bacteriological analysis of sputum obtained for 6 months from 80 patients with COPD was carried out. The first group of 31 patients with COPD was immunized simultaneously with Pneumo-23, Hiberix, Grippol plus (mean age--59.25 +/- 1.12). The second group consisted of 49 unvaccinated patients with COPD (mean age--57.16 +/- 0.98). Classical microbiological method was used in the study.
  
  
  RESULTS
  6 months after the complex vaccination a significant decrease to 35.48 +/- 8.59% of vaccinated patients, that expectorate sputum with Streptococcus pneumoniae, compared with 80.65 +/- 7.1% in unvaccinated patients with COPD was observed.
  
  
  CONCLUSIONS
  A combined vaccination against pneumococcal, haemophilus type b infection and influenza carried out with a prophylactic and therapeutic goal is recommended for patients with COPD as a part of the treatment and prophylaxis complex measures.
authors.forename: A D
authors.initials: AD
authors.lastname: Protasov
authors.forename: A V
authors.initials: AV
authors.lastname: Zhestkov
authors.forename: N E
authors.initials: NE
authors.lastname: Lavrenteva
authors.forename: M P
authors.initials: MP
authors.lastname: Kostinov
authors.forename: A A
authors.initials: AA
authors.lastname: Ryzhkov
mesh_terms: D005260:Female; D006192:Haemophilus Infections / Q000150:complications / Q000276:immunology / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D019741:Haemophilus influenzae type b / Q000302:isolation & purification; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D007251:Influenza, Human / Q000150:complications / Q000276:immunology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000150:complications / Q000276:immunology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications*; D013183:Sputum / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000302:isolation & purification; D014611:Vaccination / Q000379:methods; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; C408342:Grippol; D018073:Haemophilus Vaccines; D007252:Influenza Vaccines; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate; C514867:Hiberix